Canada markets closed

Aridis Pharmaceuticals, Inc. (ARDS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.9500-0.0220 (-2.26%)
At close: 04:00PM EST
0.9975 +0.05 (+5.00%)
After hours: 05:07PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.9720
Open0.9500
Bid0.9500 x 1800
Ask1.0900 x 800
Day's Range0.9405 - 1.0800
52 Week Range0.6800 - 4.3400
Volume203,830
Avg. Volume141,844
Market Cap19.765M
Beta (5Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)-3.2630
Earnings DateNov 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.50
  • GlobeNewswire

    Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical

    The Sudan Ebola and Marburg mAb programs were awarded approximately $190 million of BARDA funding covering manufacturing, efficacy and safety evaluations, and regulatory approval Los Gatos, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, signed an exclusive term sheet to secure international development and global

  • GlobeNewswire

    Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients

    Los Gatos, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced the closing of patient enrollment in the multiple ascending dose (MAD) and dose-ranging cohorts in the Phase 2a clinical trial of AR-501 in cystic fibrosis (CF) patients. The Company is on track to complete database lock, data analyses, and

  • GlobeNewswire

    Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases

    The Company’s superiority Phase 3 ‘ASAP-1' study of AR-301 monoclonal antibody in S. aureus pneumonia and the pending data readout will be a focus of the KOL event Los Gatos, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced its participation in H.C. Wainwright & Co.’s 2022 KOL Series (Part 8) on Tues